Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy

In lung cancer, several potential mechanisms of intrinsic and acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been explored, including mesenchymal-epithelial transition factor (MET) signaling pathway activation. On the other hand, vascular endoth...

Full description

Bibliographic Details
Main Authors: Nobuhiko Seki, Maika Natsume, Ryosuke Ochiai, Terunobu Haruyama, Masashi Ishihara, Yoko Fukasawa, Takahiko Sakamoto, Shigeru Tanzawa, Ryo Usui, Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe
Format: Article
Language:English
Published: Karger Publishers 2019-01-01
Series:Case Reports in Oncology
Subjects:
Lung cancer
EGFR mutation
MET amplification
Erlotinib
Bevacizumab
Online Access:https://www.karger.com/Article/FullText/493088

Internet

https://www.karger.com/Article/FullText/493088

Similar Items